12,436 Shares in Vaxcyte, Inc. (NASDAQ:PCVX) Acquired by J. Safra Sarasin Holding AG

Key Points

• J. Safra Sarasin Holding AG has purchased a new stake in Vaxcyte, acquiring 12,436 shares valued at approximately $470,000.
• Vaxcyte has received numerous upgrades, with analysts issuing a consensus rating of "Buy" and a price target of $136.50.
• Vaxcyte currently has a market capitalization of $4.35 billion and reported a loss of ($1.04) earnings per share for the last quarter.

J. Safra Sarasin Holding AG acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 12,436 shares of the company's stock, valued at approximately $470,000.

A number of other institutional investors have also recently bought and sold shares of the company. National Bank of Canada FI acquired a new stake in Vaxcyte in the 4th quarter worth approximately $41,000. Wells Fargo & Company MN raised its position in shares of Vaxcyte by 53.7% in the fourth quarter. Wells Fargo & Company MN now owns 72,275 shares of the company's stock valued at $5,916,000 after purchasing an additional 25,257 shares during the period. Envestnet Asset Management Inc. lifted its stake in shares of Vaxcyte by 12.5% in the fourth quarter. Envestnet Asset Management Inc. now owns 55,083 shares of the company's stock worth $4,509,000 after buying an additional 6,121 shares during the last quarter. Russell Investments Group Ltd. raised its holdings in Vaxcyte by 37.3% in the 4th quarter. Russell Investments Group Ltd. now owns 108,389 shares of the company's stock worth $8,873,000 after acquiring an additional 29,442 shares during the period. Finally, Legal & General Group Plc grew its position in shares of Vaxcyte by 13.4% in the fourth quarter. Legal & General Group Plc now owns 123,664 shares of the company's stock valued at $10,123,000 after purchasing an additional 14,574 shares during the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently commented on PCVX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $90.00 price target on shares of Vaxcyte in a research note on Tuesday, April 8th. Cantor Fitzgerald assumed coverage on shares of Vaxcyte in a research note on Tuesday, April 22nd. They set an "overweight" rating on the stock. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $136.50.

Vaxcyte Stock Performance

Shares of NASDAQ:PCVX traded down $0.73 during trading on Wednesday, reaching $33.00. 908,176 shares of the company traded hands, compared to its average volume of 1,178,552. Vaxcyte, Inc. has a 52 week low of $27.66 and a 52 week high of $121.06. The company's 50 day moving average is $34.51 and its two-hundred day moving average is $49.58.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Wednesday, August 6th. The company reported ($1.22) EPS for the quarter, missing the consensus estimate of ($1.12) by ($0.10). During the same quarter last year, the company earned ($1.10) EPS. As a group, equities analysts anticipate that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.